These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1525190)

  • 21. [Salazosulfapyridine or 5-aminosalicylic acid].
    van Hees PA
    Ned Tijdschr Geneeskd; 1987 May; 131(22):931-4. PubMed ID: 2885762
    [No Abstract]   [Full Text] [Related]  

  • 22. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB; Goa KL
    Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choosing an oral 5-aminosalicylic acid preparation for ulcerative colitis.
    Drug Ther Bull; 1992 Jun; 30(13):50-2. PubMed ID: 1628539
    [No Abstract]   [Full Text] [Related]  

  • 24. Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine.
    Perrot S; Aslangul E; Szwebel T; Gadhoum H; Romnicianu S; Le Jeunne C
    Int J Colorectal Dis; 2007 Sep; 22(9):1119-21. PubMed ID: 17440739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Thomson AB
    Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-Aminosalicylic acid in pregnancy: clinical report.
    Trallori G; d'Albasio G; Bardazzi G; Bonanomi AG; Amorosi A; Del Carlo P; Palli D; Galli M; Pacini F
    Ital J Gastroenterol; 1994 Mar; 26(2):75-8. PubMed ID: 8032081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience.
    Tolia V; Massoud N; Klotz U
    J Pediatr Gastroenterol Nutr; 1989 Apr; 8(3):333-8. PubMed ID: 2565380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mesalazine in childhood inflammatory bowel disease.
    Barden L; Lipson A; Pert P; Walker-Smith JA
    Aliment Pharmacol Ther; 1989 Dec; 3(6):597-603. PubMed ID: 2577501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.
    Sutherland LR; May GR; Shaffer EA
    Ann Intern Med; 1993 Apr; 118(7):540-9. PubMed ID: 8095128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
    Donald IP; Wilkinson SP
    Postgrad Med J; 1985 Dec; 61(722):1047-8. PubMed ID: 2869480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesalamine for ulcerative colitis.
    Med Lett Drugs Ther; 1988 May; 30(766):53-4. PubMed ID: 3283508
    [No Abstract]   [Full Text] [Related]  

  • 36. 5-Aminosalicylic acid in the treatment of inflammatory bowel disease.
    Bondesen S; Rasmussen SN; Rask-Madsen J; Nielsen OH; Lauritsen K; Binder V; Hansen SH; Hvidberg EF
    Acta Med Scand; 1987; 221(3):227-42. PubMed ID: 3296672
    [No Abstract]   [Full Text] [Related]  

  • 37. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
    Schroeder KW; Tremaine WJ; Ilstrup DM
    N Engl J Med; 1987 Dec; 317(26):1625-9. PubMed ID: 3317057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug management of ulcerative colitis.
    Barrow S; Rees SH
    BMJ; 1992 Oct; 305(6857):832. PubMed ID: 1422379
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacological bases of therapy with 5-ASA].
    Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
    Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
    [No Abstract]   [Full Text] [Related]  

  • 40. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L; Cohen H; Dooley C; Rubin P; Orchard J
    Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.